MicroDose has achieved a development milestone in collaboration with Novartis, triggering a payment under the multi-product development and licensing agreement for the MicroDose proprietary dry powder inhaler (DPI). This milestone indicates the incorporation of MicroDose’s DPI technology into a Novartis platform pulmonary device.
Under the terms of the agreement, Novartis is funding development and commercialization of products that employ MicroDose’s DPI technology for the administration of Novartis’ proprietary respiratory compounds.
Release Date: May 2, 2011
Source: Microdose Therapeutx
